{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Li W"],"pubmed_abstract":["<h4>Introduction</h4>The major challenge for universal chimeric antigen receptor T cell (UCAR-T) therapy is the inability to persist for a long time in patients leading to inferior efficacy clinically. The objective of this study was to design a novel UCAR-T cell that could avoid the occurrence of allo-rejection and provide effective resistance to allogeneic Natural Killer (NK) cell rejection, together with the validation of its safety and efficacy <i>ex vivo</i> and <i>in vivo</i>.<h4>Methods</h4>We prepared T-cell receptor (TCR), Human leukocyte antigen (HLA)-I/II triple-edited (TUCAR-T) cells and evaluated the anti-tumor efficacy ex vivo and in vivo. We measured the resistance of exogenous HLA-E expressing TUCAR-T (ETUCAR-T) to NK rejection by using an enhanced NK. Furthermore, we estab"],"journal":["Frontiers in immunology"],"pagination":["1052717"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9757162"],"repository":["biostudies-literature"],"pubmed_title":["Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection."],"pmcid":["PMC9757162"],"pubmed_authors":["Li W","Yang Z","Li Y","Shen J","Chen J","Qian C","Hong J","Zhang H","Qi Y","Zhu X","Wang G","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection.","description":"<h4>Introduction</h4>The major challenge for universal chimeric antigen receptor T cell (UCAR-T) therapy is the inability to persist for a long time in patients leading to inferior efficacy clinically. The objective of this study was to design a novel UCAR-T cell that could avoid the occurrence of allo-rejection and provide effective resistance to allogeneic Natural Killer (NK) cell rejection, together with the validation of its safety and efficacy <i>ex vivo</i> and <i>in vivo</i>.<h4>Methods</h4>We prepared T-cell receptor (TCR), Human leukocyte antigen (HLA)-I/II triple-edited (TUCAR-T) cells and evaluated the anti-tumor efficacy ex vivo and in vivo. We measured the resistance of exogenous HLA-E expressing TUCAR-T (ETUCAR-T) to NK rejection by using an enhanced NK. Furthermore, we estab","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-06-18T07:44:44.222Z","creation":"2024-11-10T03:44:46.924Z"},"accession":"S-EPMC9757162","cross_references":{"pubmed":["36532006"],"doi":["10.3389/fimmu.2022.1052717"]}}